<unk>  (trade names Complera, Eviplera) is a fixed-dose combination of antiretroviral drugs for the treatment of HIV/AIDS. The drug was co-developed by Gilead Sciences and Johnson & Johnson's Tibotec division and was approved by the Food and Drug Administration in August 2011, and by the European Medicines Agency in November 2011, for patients who have not previously been treated for HIV. It is available as a once-a-day single tablet. In the European Union it is marketed as Eviplera and in the US as Complera.
Emtricitabine/rilpivirine/tenofovir
Lamivudine/tenofovir
Doravirine/lamivudine/tenofovir
Abacavir/lamivudine/zidovudine
Bictegravir/emtricitabine/tenofovir alafenamide
Abacavir/lamivudine
Lamivudine/nevirapine/zidovudine
Dolutegravir/lamivudine/tenofovir